GTBP

Company Overview — What Does GT Biopharma, Inc. Do?

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California. GT Biopharma, Inc. (GTBP) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Michael Breen and employs approximately 8 people. With a market capitalization of $13M, GTBP is one of the notable companies in the Healthcare sector.

GT Biopharma, Inc. (GTBP) Stock Rating — Avoid (April 2026)

As of April 2026, GT Biopharma, Inc. receives a Avoid rating with a composite score of 21.5/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.GTBP ranks #4,242 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, GT Biopharma, Inc. ranks #763 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

GTBP Stock Price and 52-Week Range

GT Biopharma, Inc. (GTBP) currently trades at $0.38. The stock lost $0.02 (3.9%) in the most recent trading session. The 52-week high for GTBP is $3.85, which means the stock is currently trading -90.3% from its annual peak. The 52-week low is $0.39, putting the stock -4.2% above its annual trough. Recent trading volume was 981K shares, suggesting relatively thin trading activity.

Is GTBP Overvalued or Undervalued? — Valuation Analysis

GT Biopharma, Inc. (GTBP) carries a value factor score of 10/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 2.25x, versus the sector average of 2.75x.

At current multiples, GT Biopharma, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

GT Biopharma, Inc. Profitability — ROE, Margins, and Quality Score

GT Biopharma, Inc. (GTBP) earns a quality factor score of 15/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -450.7%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -321.8% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

GTBP Debt, Balance Sheet, and Financial Health

GT Biopharma, Inc. has a debt-to-equity ratio of 40.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 3.50x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $3M.

GTBP has a beta of 0.24, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for GT Biopharma, Inc. is 35/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

GT Biopharma, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, GT Biopharma, Inc. reported revenue of $0 and earnings per share (EPS) of $-6.68. Net income for the quarter was $-26M. Operating income came in at $-10M.

In FY 2025, GT Biopharma, Inc. reported revenue of N/A and earnings per share (EPS) of $-6.68. Net income for the quarter was $-28M. Operating income came in at $-12M.

In Q3 2025, GT Biopharma, Inc. reported revenue of N/A and earnings per share (EPS) of $1.04. Net income for the quarter was $8M. Operating income came in at $-3M.

In Q2 2025, GT Biopharma, Inc. reported revenue of N/A and earnings per share (EPS) of $-10.92. Net income for the quarter was $-30M. Operating income came in at $-2M.

Over the past 8 quarters, GT Biopharma, Inc. has reported varying levels of revenue. Investors analyzing GTBP stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

GTBP Dividend Yield and Income Analysis

GT Biopharma, Inc. (GTBP) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

GTBP Momentum and Technical Analysis Profile

GT Biopharma, Inc. (GTBP) has a momentum factor score of 11/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 68/100 reflects moderate short selling activity.

GTBP vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, GT Biopharma, Inc. (GTBP) ranks #763 out of 838 stocks based on the Blank Capital composite score. This places GTBP in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing GTBP against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full GTBP vs S&P 500 (SPY) comparison to assess how GT Biopharma, Inc. stacks up against the broader market across all factor dimensions.

GTBP Next Earnings Date

No upcoming earnings date has been announced for GT Biopharma, Inc. (GTBP) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy GTBP? — Investment Thesis Summary

The quantitative profile for GT Biopharma, Inc. suggests caution. The quality score of 15/100 flags below-average profitability. The value score of 10/100 indicates premium valuation. Momentum is weak at 11/100, a headwind for near-term performance. High volatility (stability score 35/100) increases portfolio risk.

In summary, GT Biopharma, Inc. (GTBP) earns a Avoid rating with a composite score of 21.5/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on GTBP stock.

Related Resources for GTBP Investors

Explore more research and tools: GTBP vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare GTBP head-to-head with peers: GTBP vs AZN, GTBP vs SLGL, GTBP vs VMD.